9M 2023 Financial Performance

9M 2023: APPENDIX Q3 2023: Product distribution of revenue & YoY growth DKKm FY 2021 FY 2022 Q3 2023 Q3 2022 Growth Growth (CER) % of total Q3 2023 Rexulti 2,849 3,890 1,174 1,046 12% 20% 24% Brintellix/Trintellix 3,526 4,277 1,051 1,126 (7%) 0% 21% Abilify Maintena¹) 2,420 2,964 790 771 2% 7% 16% Vyepti 492 1,004 444 282 57% 69% 9% Strategic brands 9,287 12,135 3,459 3,225 7% 14% 70% Cipralex/Lexapro 2,346 2,360 501 620 (19%) (10%) 10% Sabril 657 636 94 160 (41%) (38%) 2% Other pharmaceuticals²) 3,609 3,426 787 864 (9%) (1%) 16% Other revenue 347 277 61 49 24% 24% 1% Revenue before hedging 16,246 18,834 4,902 4,918 0% 7% 99% Effects from hedging Total revenue 34 53 16,299 (588) 18,246 50 (199) 1% 4,952 4,719 5% 7% 100% 1) Includes Abilify Asimtufii figures. 2) As of January 1, 2023, Onfi is being reported together with Other pharmaceuticals, comparative figures for 2022 have been adjusted accordingly Lundbeck

View entire presentation